Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates
CLDXCelldex Therapeutics(CLDX) ZACKS·2024-08-09 06:25

Celldex Therapeutics (CLDX) came out with a quarterly loss of 0.54pershareversustheZacksConsensusEstimateofalossof0.54 per share versus the Zacks Consensus Estimate of a loss of 0.59. This compares to loss of 0.65pershareayearago.Thesefiguresareadjustedfornon−recurringitems.Thisquarterlyreportrepresentsanearningssurpriseof8.470.65 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 8.47%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of 0.67 per share when it actually produced a loss of $0.56, delivering a surprise of 16.42%.Over the last four quarters, th ...